A growing body of evidence proved the significance of PD-1 and their ligands in a different type of cancers [24–26], and emphasize the therapeutic potential of this pathway in the treatment of patients with progressive metastatic non-small cell lung cancer (NSCLC) [27]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.